In line with previous studies [5, 35], PRAME expression was detected in multiple highly prevalent primary tumors, with frequencies >90% in skin cutaneous melanoma (SKCM), and ≥75% in endometrial, ovarian, NSCLC) SCC, and small cell lung cancer (SCLC) (Fig. 1b). Here, PRAME is linked to non-small cell lung carcinoma.